Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Immunity ; 51(1): 141-154.e6, 2019 07 16.
Article in English | MEDLINE | ID: mdl-31315032

ABSTRACT

The VH1-2 restricted VRC01-class of antibodies targeting the HIV envelope CD4 binding site are a major focus of HIV vaccine strategies. However, a detailed analysis of VRC01-class antibody development has been limited by the rare nature of these responses during natural infection and the lack of longitudinal sampling of such responses. To inform vaccine strategies, we mapped the development of a VRC01-class antibody lineage (PCIN63) in the subtype C infected IAVI Protocol C neutralizer PC063. PCIN63 monoclonal antibodies had the hallmark VRC01-class features and demonstrated neutralization breadth similar to the prototype VRC01 antibody, but were 2- to 3-fold less mutated. Maturation occurred rapidly within ∼24 months of emergence of the lineage and somatic hypermutations accumulated at key contact residues. This longitudinal study of broadly neutralizing VRC01-class antibody lineage reveals early binding to the N276-glycan during affinity maturation, which may have implications for vaccine design.


Subject(s)
AIDS Vaccines/immunology , Antibodies, Monoclonal/metabolism , Antibodies, Neutralizing/metabolism , Broadly Neutralizing Antibodies/metabolism , HIV Antibodies/metabolism , HIV Infections/immunology , HIV-1/physiology , AIDS Vaccines/genetics , Amino Acid Sequence , Antibodies, Monoclonal/genetics , Antibodies, Neutralizing/genetics , Antibody Affinity , B-Lymphocytes/immunology , Broadly Neutralizing Antibodies/genetics , CD4 Antigens/metabolism , Complementarity Determining Regions/genetics , HIV Antibodies/genetics , HIV Envelope Protein gp120/immunology , HIV Envelope Protein gp120/metabolism , Humans , Polysaccharides/metabolism , Protein Binding
2.
Sci Adv ; 4(11): eaau6769, 2018 11.
Article in English | MEDLINE | ID: mdl-30474059

ABSTRACT

Overcoming envelope metastability is crucial to trimer-based HIV-1 vaccine design. Here, we present a coherent vaccine strategy by minimizing metastability. For 10 strains across five clades, we demonstrate that the gp41 ectodomain (gp41ECTO) is the main source of envelope metastability by replacing wild-type gp41ECTO with BG505 gp41ECTO of the uncleaved prefusion-optimized (UFO) design. These gp41ECTO-swapped trimers can be produced in CHO cells with high yield and high purity. The crystal structure of a gp41ECTO-swapped trimer elucidates how a neutralization-resistant tier 3 virus evades antibody recognition of the V2 apex. UFO trimers of transmitted/founder viruses and UFO trimers containing a consensus-based ancestral gp41ECTO suggest an evolutionary root of metastability. The gp41ECTO-stabilized trimers can be readily displayed on 24- and 60-meric nanoparticles, with incorporation of additional T cell help illustrated for a hyperstable 60-mer, I3-01. In mice and rabbits, these gp140 nanoparticles induced tier 2 neutralizing antibody responses more effectively than soluble trimers.


Subject(s)
AIDS Vaccines/immunology , Drug Design , HIV Envelope Protein gp41/chemistry , HIV Infections/immunology , HIV-1/immunology , env Gene Products, Human Immunodeficiency Virus/chemistry , Animals , CHO Cells , Cricetinae , Cricetulus , Female , HIV Envelope Protein gp41/immunology , HIV Infections/prevention & control , HIV Infections/virology , Humans , Mice , Protein Conformation , Protein Multimerization , Protein Stability , Rabbits , env Gene Products, Human Immunodeficiency Virus/immunology
3.
Front Immunol ; 8: 1025, 2017.
Article in English | MEDLINE | ID: mdl-28883821

ABSTRACT

Germline precursors and intermediates of broadly neutralizing antibodies (bNAbs) are essential to the understanding of humoral response to HIV-1 infection and B-cell lineage vaccine design. Using a native-like gp140 trimer probe, we examined antibody libraries constructed from donor-17, the source of glycan-dependent PGT121-class bNAbs recognizing the N332 supersite on the HIV-1 envelope glycoprotein. To facilitate this analysis, a digital panning method was devised that combines biopanning of phage-displayed antibody libraries, 900 bp long-read next-generation sequencing, and heavy/light (H/L)-paired antibodyomics. In addition to single-chain variable fragments resembling the wild-type bNAbs, digital panning identified variants of PGT124 (a member of the PGT121 class) with a unique insertion in the heavy chain complementarity-determining region 1, as well as intermediates of PGT124 exhibiting notable affinity for the native-like trimer and broad HIV-1 neutralization. In a competition assay, these bNAb intermediates could effectively compete with mouse sera induced by a scaffolded BG505 gp140.681 trimer for the N332 supersite. Our study thus reveals previously unrecognized lineage complexity of the PGT121-class bNAbs and provides an array of library-derived bNAb intermediates for evaluation of immunogens containing the N332 supersite. Digital panning may prove to be a valuable tool in future studies of bNAb diversity and lineage development.

4.
Nature ; 548(7665): 108-111, 2017 08 03.
Article in English | MEDLINE | ID: mdl-28726771

ABSTRACT

No immunogen to date has reliably elicited broadly neutralizing antibodies to HIV in humans or animal models. Advances in the design of immunogens that antigenically mimic the HIV envelope glycoprotein (Env), such as the soluble cleaved trimer BG505 SOSIP, have improved the elicitation of potent isolate-specific antibody responses in rabbits and macaques, but so far failed to induce broadly neutralizing antibodies. One possible reason for this failure is that the relevant antibody repertoires are poorly suited to target the conserved epitope regions on Env, which are somewhat occluded relative to the exposed variable epitopes. Here, to test this hypothesis, we immunized four cows with BG505 SOSIP. The antibody repertoire of cows contains long third heavy chain complementary determining regions (HCDR3) with an ultralong subset that can reach more than 70 amino acids in length. Remarkably, BG505 SOSIP immunization resulted in rapid elicitation of broad and potent serum antibody responses in all four cows. Longitudinal serum analysis for one cow showed the development of neutralization breadth (20%, n = 117 cross-clade isolates) in 42 days and 96% breadth (n = 117) at 381 days. A monoclonal antibody isolated from this cow harboured an ultralong HCDR3 of 60 amino acids and neutralized 72% of cross-clade isolates (n = 117) with a potent median IC50 of 0.028 µg ml-1. Breadth was elicited with a single trimer immunogen and did not require additional envelope diversity. Immunization of cows may provide an avenue to rapidly generate antibody prophylactics and therapeutics to address disease agents that have evolved to avoid human antibody responses.


Subject(s)
Antibodies, Neutralizing/biosynthesis , Antibodies, Neutralizing/isolation & purification , Cattle/immunology , HIV/immunology , Immunization , Amino Acid Sequence , Animals , Antibodies, Neutralizing/chemistry , Antibodies, Neutralizing/immunology , HEK293 Cells , HIV Envelope Protein gp160/immunology , Humans
5.
PLoS Pathog ; 13(2): e1006212, 2017 02.
Article in English | MEDLINE | ID: mdl-28225819

ABSTRACT

Among broadly neutralizing antibodies to HIV, 10E8 exhibits greater neutralizing breadth than most. Consequently, this antibody is the focus of prophylactic/therapeutic development. The 10E8 epitope has been identified as the conserved membrane proximal external region (MPER) of gp41 subunit of the envelope (Env) viral glycoprotein and is a major vaccine target. However, the MPER is proximal to the viral membrane and may be laterally inserted into the membrane in the Env prefusion form. Nevertheless, 10E8 has not been reported to have significant lipid-binding reactivity. Here we report x-ray structures of lipid complexes with 10E8 and a scaffolded MPER construct and mutagenesis studies that provide evidence that the 10E8 epitope is composed of both MPER and lipid. 10E8 engages lipids through a specific lipid head group interaction site and a basic and polar surface on the light chain. In the model that we constructed, the MPER would then be essentially perpendicular to the virion membrane during 10E8 neutralization of HIV-1. As the viral membrane likely also plays a role in selecting for the germline antibody as well as size and residue composition of MPER antibody complementarity determining regions, the identification of lipid interaction sites and the MPER orientation with regard to the viral membrane surface during 10E8 engagement can be of great utility for immunogen and therapeutic design.


Subject(s)
Antibodies, Neutralizing/chemistry , Antibodies, Neutralizing/immunology , HIV Antibodies/chemistry , HIV Antibodies/immunology , HIV-1/immunology , Antibodies, Blocking/chemistry , Antibodies, Blocking/immunology , HIV Envelope Protein gp41/immunology , Humans , Protein Conformation , Surface Plasmon Resonance , X-Ray Diffraction
6.
Cell ; 166(6): 1445-1458.e12, 2016 Sep 08.
Article in English | MEDLINE | ID: mdl-27610569

ABSTRACT

A vaccine that elicits broadly neutralizing antibodies (bNAbs) against HIV-1 is likely to be protective, but this has not been achieved. To explore immunization regimens that might elicit bNAbs, we produced and immunized mice expressing the predicted germline PGT121, a bNAb specific for the V3-loop and surrounding glycans on the HIV-1 spike. Priming with an epitope-modified immunogen designed to activate germline antibody-expressing B cells, followed by ELISA-guided boosting with a sequence of directional immunogens, native-like trimers with decreasing epitope modification, elicited heterologous tier-2-neutralizing responses. In contrast, repeated immunization with the priming immunogen did not. Antibody cloning confirmed elicitation of high levels of somatic mutation and tier-2-neutralizing antibodies resembling the authentic human bNAb. Our data establish that sequential immunization with specifically designed immunogens can induce high levels of somatic mutation and shepherd antibody maturation to produce bNAbs from their inferred germline precursors.


Subject(s)
AIDS Vaccines/immunology , Antibodies, Neutralizing/immunology , Antigens, Viral/administration & dosage , HIV Antibodies/immunology , HIV-1/immunology , Immunization , Immunoglobulins/genetics , Amino Acid Sequence , Animals , Antigens, Viral/genetics , Antigens, Viral/immunology , B-Lymphocytes/immunology , Cloning, Molecular , DNA Primers/chemistry , Epitopes/immunology , Gene Knock-In Techniques , HIV Infections/immunology , Mice , Mutation , Sequence Alignment
7.
Cell ; 166(6): 1459-1470.e11, 2016 Sep 08.
Article in English | MEDLINE | ID: mdl-27610570

ABSTRACT

Induction of broadly neutralizing antibodies (bnAbs) is a primary goal of HIV vaccine development. VRC01-class bnAbs are important vaccine leads because their precursor B cells targeted by an engineered priming immunogen are relatively common among humans. This priming immunogen has demonstrated the ability to initiate a bnAb response in animal models, but recall and maturation toward bnAb development has not been shown. Here, we report the development of boosting immunogens designed to guide the genetic and functional maturation of previously primed VRC01-class precursors. Boosting a transgenic mouse model expressing germline VRC01 heavy chains produced broad neutralization of near-native isolates (N276A) and weak neutralization of fully native HIV. Functional and genetic characteristics indicate that the boosted mAbs are consistent with partially mature VRC01-class antibodies and place them on a maturation trajectory that leads toward mature VRC01-class bnAbs. The results show how reductionist sequential immunization can guide maturation of HIV bnAb responses.


Subject(s)
Antibodies, Neutralizing/immunology , B-Lymphocytes/immunology , HIV Antibodies/immunology , HIV-1/immunology , Vaccines, Synthetic/immunology , Adult , Amino Acid Sequence , Animals , Antibodies, Neutralizing/genetics , Antigens, Viral/immunology , Female , HIV Antibodies/blood , HIV Antibodies/genetics , Humans , Male , Mice , Mice, Transgenic , Mutation , Sequence Alignment , Vaccines, Synthetic/administration & dosage
9.
PLoS Pathog ; 12(8): e1005815, 2016 08.
Article in English | MEDLINE | ID: mdl-27560183

ABSTRACT

An optimal HIV vaccine should induce broadly neutralizing antibodies (bnAbs) that neutralize diverse viral strains and subtypes. However, potent bnAbs develop in only a small fraction of HIV-infected individuals, all contain rare features such as extensive mutation, insertions, deletions, and/or long complementarity-determining regions, and some are polyreactive, casting doubt on whether bnAbs to HIV can be reliably induced by vaccination. We engineered two potent VRC01-class bnAbs that minimized rare features. According to a quantitative features frequency analysis, the set of features for one of these minimally mutated bnAbs compared favorably with all 68 HIV bnAbs analyzed and was similar to antibodies elicited by common vaccines. This same minimally mutated bnAb lacked polyreactivity in four different assays. We then divided the minimal mutations into spatial clusters and dissected the epitope components interacting with those clusters, by mutational and crystallographic analyses coupled with neutralization assays. Finally, by synthesizing available data, we developed a working-concept boosting strategy to select the mutation clusters in a logical order following a germline-targeting prime. We have thus developed potent HIV bnAbs that may be more tractable vaccine goals compared to existing bnAbs, and we have proposed a strategy to elicit them. This reductionist approach to vaccine design, guided by antibody and antigen structure, could be applied to design candidate vaccines for other HIV bnAbs or protective Abs against other pathogens.


Subject(s)
AIDS Vaccines/immunology , Antibodies, Neutralizing/immunology , Drug Design , HIV Antibodies/immunology , HIV-1/immunology , Amino Acid Sequence , Antibodies, Neutralizing/genetics , HIV Antibodies/genetics , HIV Infections/immunology , High-Throughput Screening Assays , Humans , Models, Molecular , Mutation
10.
Immunity ; 45(1): 31-45, 2016 07 19.
Article in English | MEDLINE | ID: mdl-27438765

ABSTRACT

The dense patch of high-mannose-type glycans surrounding the N332 glycan on the HIV envelope glycoprotein (Env) is targeted by multiple broadly neutralizing antibodies (bnAbs). This region is relatively conserved, implying functional importance, the origins of which are not well understood. Here we describe the isolation of new bnAbs targeting this region. Examination of these and previously described antibodies to Env revealed that four different bnAb families targeted the (324)GDIR(327) peptide stretch at the base of the gp120 V3 loop and its nearby glycans. We found that this peptide stretch constitutes part of the CCR5 co-receptor binding site, with the high-mannose patch glycans serving to camouflage it from most antibodies. GDIR-glycan bnAbs, in contrast, bound both (324)GDIR(327) peptide residues and high-mannose patch glycans, which enabled broad reactivity against diverse HIV isolates. Thus, as for the CD4 binding site, bnAb effectiveness relies on circumventing the defenses of a critical functional region on Env.


Subject(s)
Antibodies, Neutralizing/immunology , Binding Sites, Antibody/immunology , HIV Antibodies/immunology , HIV Envelope Protein gp120/metabolism , HIV Infections/immunology , HIV-1/immunology , Polysaccharides/metabolism , Amino Acid Motifs , CD4 Antigens/metabolism , Epitope Mapping , Epitopes/metabolism , Genetic Engineering , HEK293 Cells , HIV Envelope Protein gp120/immunology , Humans , Immunity, Humoral , Immunologic Memory , Peptide Fragments/metabolism , Polysaccharides/immunology , Protein Binding , Receptors, CCR5/metabolism
11.
Proc Natl Acad Sci U S A ; 111(49): 17624-9, 2014 Dec 09.
Article in English | MEDLINE | ID: mdl-25422458

ABSTRACT

Broadly neutralizing antibodies (bnAbs) targeting the trimer apex of HIV envelope are favored candidates for vaccine design and immunotherapy because of their great neutralization breadth and potency. However, methods of isolating bnAbs against this site have been limited by the quaternary nature of the epitope region. Here we report the use of a recombinant HIV envelope trimer, BG505 SOSIP.664 gp140, as an affinity reagent to isolate quaternary-dependent bnAbs from the peripheral blood mononuclear cells of a chronically infected donor. The newly isolated bnAbs, named "PGDM1400-1412," show a wide range of neutralization breadth and potency. One of these variants, PGDM1400, is exceptionally broad and potent with cross-clade neutralization coverage of 83% at a median IC50 of 0.003 µg/mL. Overall, our results highlight the utility of BG505 SOSIP.664 gp140 as a tool for the isolation of quaternary-dependent antibodies and reveal a mosaic of antibody responses against the trimer apex within a clonal family.


Subject(s)
Antibodies, Neutralizing/immunology , HIV Antibodies/immunology , HIV Envelope Protein gp120/immunology , Amino Acid Sequence , B-Lymphocytes/immunology , Base Sequence , Cross Reactions , Epitopes/chemistry , Genetic Variation , HIV Infections/immunology , Humans , Immunologic Memory , Inhibitory Concentration 50 , Leukocytes, Mononuclear/cytology , Models, Molecular , Molecular Conformation , Molecular Sequence Data , Neutralization Tests , Peptide Library , Phylogeny , Protein Folding , Recombinant Proteins/immunology , Sequence Homology, Amino Acid
12.
Sci Transl Med ; 6(236): 236ra63, 2014 May 14.
Article in English | MEDLINE | ID: mdl-24828077

ABSTRACT

Broadly neutralizing monoclonal antibodies (bnmAbs) that target the high-mannose patch centered around the glycan at position 332 on HIV Env are promising vaccine leads and therapeutic candidates because they effectively protect against mucosal SHIV challenge and strongly suppress SHIV viremia in established infection in macaque models. However, these antibodies demonstrate varying degrees of dependency on the N332 glycan site, and the origins of their neutralization breadth are not always obvious. By measuring neutralization on an extended range of glycan site viral variants, we found that some bnmAbs can use alternate N-linked glycans in the absence of the N332 glycan site and therefore neutralize a substantial number of viruses lacking the site. Furthermore, many of the antibodies can neutralize viruses in which the N332 glycan site is shifted to the 334 position. Finally, we found that a combination of three antibody families that target the high-mannose patch can lead to 99% neutralization coverage of a large panel of viruses containing the N332/N334 glycan site and up to 66% coverage for viruses that lack the N332/N334 glycan site. The results indicate that a diverse response against the high-mannose patch may provide near-equivalent coverage as a combination of bnmAbs targeting multiple epitopes. Additionally, the ability of some bnmAbs to use other N-linked glycan sites can help counter neutralization escape mediated by shifting of glycosylation sites. Overall, this work highlights the importance of promiscuous glycan binding properties in bnmAbs to the high-mannose patch for optimal antiviral activity in either protective or therapeutic modalities.


Subject(s)
Antibodies, Neutralizing/chemistry , HIV Envelope Protein gp120/immunology , HIV Infections/immunology , Polysaccharides/chemistry , Antibodies, Monoclonal/chemistry , Binding Sites , Enzyme-Linked Immunosorbent Assay , Epitopes/chemistry , Glycosylation , HIV Antibodies/chemistry , HIV Envelope Protein gp120/chemistry , HIV Seropositivity , HIV-1/immunology , Humans , Immunoglobulin G/chemistry , Inhibitory Concentration 50 , Mannose/chemistry , Molecular Sequence Data , Neutralization Tests , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...